Icotinib
- Generic Name
- Icotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21N3O4
- CAS Number
- 610798-31-7
- Unique Ingredient Identifier
- 9G6U5L461Q
- Background
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
...
- Indication
Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.
- Associated Conditions
- -
- Associated Therapies
- -
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- People's Hospital of Guangxi
- Target Recruit Count
- 80
- Registration Number
- NCT02407366
- Locations
- 🇨🇳
The people's Hospital of the Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT02404675
- Locations
- 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, China
Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- First People's Hospital of Hangzhou
- Target Recruit Count
- 130
- Registration Number
- NCT02375581
- Locations
- 🇨🇳
Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China
Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 26
- Registration Number
- NCT02362230
- Locations
- 🇨🇳
Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, China
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT02328261
Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation
- Conditions
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT02283424
- Locations
- 🇨🇳
PLA General Hospital, BeiJing, China
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02278458
- Locations
- 🇨🇳
Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳Bethune First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT02272127
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Icotinib for Completed Resected IB NSCLC With EGFR Mutation
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 128
- Registration Number
- NCT02264210
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 60
- Registration Number
- NCT02191059
- Locations
- 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.